Euglycemic Ketoacidosis: A Complete Patient Guide

Overview

Euglycemic ketoacidosis (EKA) is a form of metabolic acidosis in which the body produces high levels of ketone bodies while the blood glucose level remains normal or only mildly elevated (typically <140 mg/dL). It shares the same biochemical pathway as classic diabetic ketoacidosis (DKA) but without the marked hyperglycemia that usually alerts clinicians.

Although historically considered rare, the incidence of EKA has risen over the past decade, largely due to the widespread use of sodium‑glucose cotransporter‑2 (SGLT‑2) inhibitors for type 2 diabetes. A 2022 meta‑analysis of 34 studies estimated that 1–2 % of patients on SGLT‑2 inhibitors experience EKA annually, with higher rates (up to 5 %) in peri‑operative or fasting states.

People most affected include:

• Adults with type 1 or type 2 diabetes taking SGLT‑2 inhibitors (e.g., canagliflozin, dapagliflozin, empagliflozin).
• Patients with type 1 diabetes who are on a very low‑carbohydrate or ketogenic diet.
• Individuals who are pregnant, have prolonged fasting, severe vomiting/diarrhea, or acute illness (e.g., infection, stroke).

Symptoms

Symptoms of EKA overlap with those of classic DKA, but the lack of high blood sugar can delay recognition. The following list is comprehensive; not every patient will have all signs.

General & Neurologic

• Fatigue or weakness – due to energy depletion.
• Headache – often described as dull or throbbing.
• Dizziness or light‑headedness – may worsen when standing.
• Confusion, difficulty concentrating, or slowed thinking – result of cerebral acidosis.
• Fainting (syncope) – in severe dehydration.

Gastrointestinal

• Nausea and vomiting (often persistent).
• Abdominal pain or cramping.
• Loss of appetite.

Respiratory

• Rapid, deep breathing (Kussmaul respirations) as the body tries to blow off CO₂.

Urinary & Metabolic

• Polyuria (increased urination) despite normal glucose.
• Polydipsia (excessive thirst).
• Fruity or acetone‑like odor on the breath.
• Unexplained weight loss (usually short‑term).

Cardiovascular

• Palpitations or rapid heart rate (tachycardia).
• Low blood pressure (hypotension) due to volume depletion.

Causes and Risk Factors

EKA results from an imbalance between ketone production and the body’s ability to clear them, occurring without the hyperglycemia that normally drives osmotic diuresis. Key mechanisms include:

• SGLT‑2 inhibitor therapy – These drugs increase urinary glucose excretion, lowering plasma glucose, which reduces insulin secretion and raises glucagon, prompting ketogenesis.
• Low‑carbohydrate/ketogenic diets – Reduced carbohydrate intake lowers insulin and raises free fatty acids, fueling ketone production.
• Prolonged fasting or starvation – Depletes glycogen stores, shifting metabolism toward fat oxidation.
• Pregnancy – Hormonal changes increase insulin resistance and lipolysis, heightening ketone risk.
• Acute illness or infection – Stress hormones (cortisol, epinephrine) antagonize insulin.
• Alcohol binge drinking – Alcoholic ketoacidosis can mimic EKA.
• Medications that reduce insulin – e.g., high‑dose glucocorticoids, certain antipsychotics.

Who is most at risk?

• Adults 45‑70 years old on SGLT‑2 inhibitors (especially with type 2 diabetes).
• Patients with type 1 diabetes who self‑prescribe SGLT‑2 inhibitors off‑label.
• Pregnant women with type 1 or type 2 diabetes.
• Individuals undergoing major surgery or who have had recent anesthesia.
• Those with chronic vomiting, severe diarrhea, or recent high‑dose alcohol consumption.

Diagnosis

Because blood glucose may be normal, clinicians rely on a combination of clinical suspicion and specific laboratory tests.

Key Diagnostic Criteria

1. Blood pH < 7.3 or bicarbonate < 15 mmol/L (metabolic acidosis).
2. Elevated serum or urinary ketones (beta‑hydroxybutyrate > 3 mmol/L is typical).
3. Blood glucose ≤ 200 mg/dL (often < 140 mg/dL).
4. Absence of other causes of acidosis (e.g., lactic acidosis, renal failure).

Laboratory Tests

• Basic metabolic panel – assesses electrolytes, anion gap, and kidney function.
• Serum beta‑hydroxybutyrate – more accurate than urine dipstick for ketones.
• Arterial blood gas (ABG) – confirms acidemia and evaluates respiratory compensation.
• Serum lactate – to rule out concurrent lactic acidosis.
• C‑peptide and insulin levels (optional) – help determine endogenous insulin reserve.
• Urinalysis – detects ketonuria; may also show glucosuria if SGLT‑2 inhibitors are present.

Imaging & Other Tests

Imaging is not routinely required unless an alternative diagnosis (e.g., intra‑abdominal infection) is suspected. A chest X‑ray or abdominal CT may be ordered based on clinical presentation.

Treatment Options

Prompt treatment mirrors that of classic DKA but with special attention to the normal glucose level.

Initial Stabilization (First 1–2 hours)

• Intravenous (IV) fluids – 0.9 % saline bolus 15–20 mL/kg, then titrated to maintain perfusion and correct electrolyte deficits.
• Electrolyte replacement – especially potassium; hypokalemia must be corrected before insulin administration.
• Insulin therapy – low‑dose continuous IV insulin (0.05–0.1 U/kg/h). Because glucose is not high, dextrose (5 % dextrose in saline) is added once blood glucose falls < 200 mg/dL to prevent hypoglycemia while continuing ketosis resolution.

Ongoing Management

• Monitor blood glucose, serum ketones, pH, bicarbonate, and electrolytes every 2–4 hours until stable.
• Transition to subcutaneous insulin once anion gap normalizes and the patient can tolerate oral intake.
• Discontinue SGLT‑2 inhibitor (and any other precipitating medication) during the acute episode.

Adjunct Therapies

• Bicarbonate therapy – only if pH < 7.0 or severe hemodynamic compromise (controversial; use per provider discretion).
• Thiamine – 100 mg IV daily if chronic alcohol use is present.

Post‑Acute Care

• Re‑evaluate diabetes regimen – consider alternative glucose‑lowering agents if SGLT‑2 inhibitors are to be re‑started.
• Patient education on sick‑day rules (e.g., extra fluid, checking ketones).
• Schedule follow‑up with endocrinology within 1–2 weeks.

Living with Euglycemic Ketoacidosis

After recovery, patients need a practical plan to avoid recurrence.

Daily Management Tips

• Frequent blood glucose & ketone checks – especially during illness, fasting, or after vigorous exercise.
• Stay hydrated – aim for at least 2–3 L of fluid daily unless fluid‑restricted for other reasons.
• Balanced carbohydrate intake – avoid extreme low‑carb diets unless supervised by a dietitian.
• Use a **sick‑day protocol**:
  • If vomiting, fever > 38 °C, or inability to eat for > 12 h, double oral fluids, monitor ketones, and contact your provider.
• Medication review – keep an up‑to‑date list; discuss any new drugs with your physician.
• Carry a medical alert card that mentions “Euglycemic Ketoacidosis – on SGLT‑2 inhibitor” for emergency personnel.

Physical Activity

Exercise is beneficial but should be approached cautiously:

• Check glucose and ketones before and after prolonged workouts.
• Consume a carbohydrate snack (15‑30 g) if ketones rise above 0.6 mmol/L or if you feel light‑headed.

Psychological Support

Living with a potentially life‑threatening condition can cause anxiety. Consider counseling, diabetes support groups, or therapist referral.

Prevention

Preventing EKA hinges on recognizing high‑risk situations and modifying behaviors.

• Medication management – Temporarily stop SGLT‑2 inhibitors before surgery, before fasting > 24 h, or during severe illness (per FDA guidance).
• Educate yourself – Learn how to test urine/serum ketones and interpret results.
• Maintain a moderate carbohydrate intake – Typically 45‑60 % of daily calories unless a dietitian advises otherwise.
• Hydration – Keep a water bottle handy; set reminders if you tend to forget.
• Regular follow‑up – Quarterly endocrinology visits for medication adjustments.
• Pregnancy considerations – Pregnant patients on SGLT‑2 inhibitors should switch to safer alternatives early in gestation.

Complications

If untreated or delayed, EKA can lead to the same serious complications as DKA.

• Severe dehydration – leading to acute kidney injury.
• Electrolyte disturbances – especially hypokalemia, which can cause arrhythmias.
• Cerebral edema – rare but life‑threatening, more common in younger patients.
• Cardiovascular collapse – due to combined effects of acidosis, hypotension, and electrolyte imbalance.
• Infection – hyperglycemia‑independent immune dysfunction can predispose to sepsis.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Diabetic ketoacidosis.” 2023; CDC. “SGLT2 inhibitor safety.” 2022; NIH. “Ketone bodies and metabolism.” 2021; WHO. “Guidelines for management of diabetes emergencies.” 2022; Cleveland Clinic. “Euglycemic ketoacidosis: What you need to know.” 2024; JAMA Netw Open. “Incidence of euglycemic ketoacidosis with SGLT‑2 inhibitors.” 2022.